UNASSIGNED: Objective   We performed a retrospective chart analysis in neonates routinely treated with @entity4677 ( @entity29279 ) in a university setting. @entity1 and Methods We assessed clinical characteristics of the included neonates. Documented @entity29279 doses and the duration of treatment were evaluated. To assess @entity29279 effectiveness, we compared the need of any additional anticonvulsant as co- and rescue therapies before and following the initiation of @entity29279 treatment. To assess @entity29279 tolerance, we sought to identify documented adverse drug reactions resulting in a termination of @entity29279 treatment. Results   We analyzed a total of 72 neonates receiving @entity29279 with a median gestational age at initiation of @entity29279 treatment of 30 (4/7) gestational weeks (min., 24(5/7)/max., 43(0/7) weeks). @entity29279 was applied in target doses of 41.7 mg/kg/d (min., 14.4/max., 106.2 mg/kg/d). @entity1 received @entity29279 treatment at hospital for a median of 28 days (min., 1/max., 195 days). Additional anticonvulsant therapy decreased a week after @entity29279 treatment was initiated (p   =   0.008). We did not find any cases of terminated @entity29279 treatment resulting from adverse drug reactions. Conclusion   Long term use of high @entity29279 doses is rather frequent in immature neonates. Our data indicate good effectiveness and a low risk of adverse drug reactions.

Use of XXXX in Neonates in Clinical Practice: A Retrospective Study at a German University Hospital.

@entity1 :: ('9606', 'Species') :: ['Patients'] @entity4677 :: ('MESH:C026098', 'Chemical') :: ['levetiracetam'] @entity29279 :: ('C026098', 'Chemical') :: ['LEV']
@entity4677 :: (MESH:C026098,Chemical) :: ['Levetiracetam']
